LENZ Therapeutics Inc. (LENZ)
21.80
0.26 (1.21%)
At close: Mar 04, 2025, 9:54 AM
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 22, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Evert B. Schimmelpennink |
Contact Details
Address: 445 Marine View Avenue Del Mar, California United States | |
| Website | https://www.lenz-tx.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary & Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Breianna Bowen | Vice President of Human Resources |
| David Murphy | Vice President of Marketing |
| Domenick Porfidia | Vice President of Sales |
| James W. McCollum | Co-Founder & Director |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Marvin J. Garrett | Senior Vice President of Regulatory & Quality |
| Shawn Olsson | Chief Commercial Officer |